Three Plenary Sessions were presented recently at the 2025 Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), which focused specifically on new advances and practical clinical applications in the field of hematologic malignancies. The theme of SOHO 2025 was “Unleashing AI, Genomics, Targets, and Immune Engineering.” (See news coverage from this important meeting at ASCOPost.com and in future issues of The ASCO Post.)
Sagar Lonial, MD, FACP, FASCO
Plenary I featured Sagar Lonial, MD, FACP, FASCO, who was the recipient of the Emil J Freireich Distinguished Pioneer Award. The Freireich Award recognizes SOHO members who have significantly advanced the mission of the society. An internationally recognized leading authority in multiple myeloma treatment and research, Dr. Lonial collaborates with leadership as Chief Medical Officer to coordinate and enhance clinical services and patient care throughout Winship Cancer Institute of Emory University in Atlanta.
Jennifer Brown, MD, PhD
Plenary II featured Jennifer Brown, MD, PhD, who was the recipient of the Michael J. Keating Outstanding Achievement Award. The Keating Award recognizes an individual who has significantly contributed to the advancement of cancer treatment and research in the field of hematologic oncology. Dr. Brown is Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and the Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston.
Charles G. Mullighan, MBBS (Hons), MSc, MD
Plenary III featured Charles G. Mullighan, MBBS (Hons), MSc, MD, whose session was entitled “Genomics and Futures of Personalized Therapy in ALL.” Dr. Mullighan is Deputy Director of the St. Jude Children’s Research Comprehensive Cancer Center in Memphis. He currently serves as co-leader of the Cancer Center’s Hematological Malignancies Program. Dr. Mullighan’s research focuses on defining the landscape of genomic and epigenomic alterations that drive the pathogenesis of acute lymphoblastic leukemia (ALL) and related disorders and then using this information to develop experimental models that faithfully recapitulate the genetics of human ALL.
